A Pompidou

Publications (10)17.22 Total impact

• Source

  Available from: Jean-Marc Pinard

  Article: De novo t(X;21)(q28;q11) in a girl with phenotypic features of Williams-Beuren syndrome.

  L Telvi, J M Pinard, R Ion, P M Sinet, A Nicole, J Feingold, O Dulac, A Pompidou, G Ponsot
  [show abstract] [hide abstract]
  ABSTRACT: We describe a female infant with mental retardation and some of the phenotypic features of Williams-Beuren syndrome. Chromosome analysis showed t(X;21)(q28;q11). Diagnosis, inactivation of the X chromosome, and possible involvement of the translocation breakpoints in the pathogenesis of this syndrome are discussed.
  Journal of Medical Genetics 11/1992; 29(10):747-9. · 6.36 Impact Factor
• Article: Segregation of three reciprocal translocations in the same family: t(3;4), t(5;10), and t(15;21).

  L Telvi, M Folhen, O Raoul, J Feingold, G Ponsot, A Pompidou, M O Rethoré, J Lejeune
  [show abstract] [hide abstract]
  ABSTRACT: A male infant with static antenatal encephalopathy and epilepsy was found to have a duplication of 5p12----5pter and deficiency of 10p13----10pter. Each of his parents was a carrier of a balanced reciprocal translocation. A third translocation was found in the maternal grandfather. The pedigree of each translocation and the segregation of parental reciprocal translocations are discussed.
  American Journal of Medical Genetics 04/1992; 42(5):716-9.
• Article: Immunosuppressive effects of isoprinosine in man: a comparison to chlorambucil effects in multiple sclerosis.

  A Pompidou, G Rancurel, M C Delsaux, C Meunier, L Telvi, V Cour, A Buge
  [show abstract] [hide abstract]
  ABSTRACT: Immunological and clinical functions were studied over a 2 year period in conjunction with a placebo controlled trial of isoprinosine and chlorambucil in 21 patients with exacerbating remitting multiple sclerosis. Laboratory and clinical evaluations were performed at 3 month intervals and during relapses. In placebo-treated patients, the decrease in circulating T8+ cells was maximum during relapses, T lymphocyte function was impaired, and five of the six patients experienced clinical worsening. Chlorambucil treatment was responsible for a decrease in circulating T4+ and T8+ cells; nevertheless, T lymphocyte function was slightly improved during relapses. The alterations of delayed hypersensitivity responses were not accompanied by improvement in relapse rate or in intensity and major side effects: mainly infections with leukopenia and thrombocytopenia. During isoprinosine therapy, a regulation of circulating T lymphocytes and cell proliferation occurred. The higher level of circulating T cells was related to the increase in T4+ and T8+ cells, which did not decrease during relapses. The absence of Leu 7+ cell modifications suggest that NK were numerically unaffected by isoprinosine therapy and that in vivo regulation of circulating T suppressor cells was performed by this treatment. Four out of seven patients did not experience any relapse during the duration of the trial. In relapsing patients, the frequency and duration of the relapses were significantly different from that of other patients. A reduction of the disease progression was observed without any side effects. While no conclusion can be drawn on the long-term effectiveness, the results of this pilot study are consistent indicators of the immunological and clinical beneficial effects of isoprinosine therapy in patients with exacerbating remitting multiple sclerosis.
  Cancer detection and prevention. Supplement: official publication of the International Society for Preventive Oncology, Inc 02/1987; 1:377-83.
• Article: Immunological effects of isoprinosine as a pulse immunotherapy in melanoma and ARC patients.

  A Pompidou, C Soubrane, V Cour, L Telvi, C Meunier, C Jacquillat
  [show abstract] [hide abstract]
  ABSTRACT: Immunomodulatory effect of Isoprinosine are presented in melanoma and HTLV-III/LAV infected patients. Isoprinosine (50 mg/kg) was used as a pulse immunotherapy according to two different schedules: A) 5 days every 15 days and B) 5 days every 15 days for 2 months, then 5 days every 2 months. The patients' immunological profiles were tested before and during the treatment in terms of T-cell subsets, cell number requirement for PHA-induced proliferation, and delayed hypersensitivity reaction to recall antigens. Primary malignant melanoma patients are randomized between surgery alone or associated to isotherapy (schedule A or B). Schedule A, after an initial improvement of surgery-induced immune deficiency, is responsible for an immunodepression, whereas schedule B determines a prolonged restoration in immune responses in melanoma and AIDS related complex or Kaposi sarcoma patients as well. In vitro effects of Isoprinosine on HTLV-III/LAV infection are presented. These data exhibit 1) the need of an immunological follow-up during isotherapy and 2) the immunological benefit of a pulse immunotherapy during acquired immunodeficiencies related to cancer surgery or to HTLV-III/LAV infection in man.
  Cancer detection and prevention. Supplement: official publication of the International Society for Preventive Oncology, Inc 02/1987; 1:457-62.
• Article: [Clinical and immunological improvement of remittent multiple sclerosis by isoprinosine. Randomized pilot study].

  A Pompidou, G Rancurel, M C Delsaux, L Telvi, V Cour, A Buge
  La Presse Médicale 06/1986; 15(20):930-1. · 0.67 Impact Factor
• Article: Influence of immunomodulators on T lymphocyte differentiation in ARC patients and resistance to LAV/HTLV III infection.

  A Pompidou, J M Lang, L Telvi, M C Delsaux, P Sarin
  [show abstract] [hide abstract]
  ABSTRACT: Isoprinosine and Imuthiol are non mitogenic immunomodulators active on T cell differentiation. In ARC patients, they modulate the circulating T cell receptor complex in terms of OKT4+ phenotype induction. This effect is not responsible for any expansion of the target population but for a partial inhibition of in vitro infection with LAV/HTLV III viral particles. At a clinical level, this means that these drugs may prove helpful in ARC patients when the virus has infected only a few helper cells.
  Comparative Immunology Microbiology and Infectious Diseases 02/1986; 9(2-3):263-7. · 2.34 Impact Factor
• Source

  Available from: aacrjournals.org

  Article: Isoprinosine and Imuthiol, two potentially active compounds in patients with AIDS-related complex symptoms.

  A Pompidou, M C Delsaux, L Telvi, B Mace, F Coutance, A Falkenrodt, J M Lang
  [show abstract] [hide abstract]
  ABSTRACT: Isoprinosine and Imuthiol are immunomodulators with a unique effect on T-cells. The possibility of using them in treating patients with acquired immunodeficiency syndrome related complex (ARC) was initially examined regarding their in vitro effects on peripheral blood mononuclear cells. In six ARC patients Isoprinosine (100 micrograms/ml) and Imuthiol (10 pg/ml) induced in vitro an early chromatin activation as measured by nuclear refringency test and potentiated phytohemagglutinin (5 micrograms/ml) in the same 20-min assay in the absence of fetal calf serum. In all patients an early phytohemagglutinin induced chromatin dispersion was observed with a dose related response before interleukin 2 production can occur. Isoprinosine and Imuthiol increased significantly both the percentage and the absolute number of T4+ cells when peripheral blood mononuclear cells were incubated for 4 days in RPMI supplemented with 10% fetal calf serum. No changes in T8+ cells were noted. Three homosexual ARC patients were then treated p.o. with Imuthiol (5-10 mg/kg/week) for 4 to 6 months. Without any deleterious effect a clinical improvement (in terms of adenopathy and opportunistic infection regression) and restoration of the response to recall antigens were observed in all three patients. One patient with less than 500 T4+ lymphocytes/mm3 exhibited a complete restoration of OKT profiles. In such patients clinical and immunological effects of Isoprinosine have already been reported by others. Altogether these preliminary results indicate that more data should be obtained on the effects of these two agents in ARC patients.
  Cancer Research 10/1985; 45(9 Suppl):4671s-4673s. · 7.86 Impact Factor
• Article: The generation and regulation of human T lymphocytes by Imuthiol. Evidence from an in vitro differentiation induction system.

  A Pompidou, N Duchet, M D Cooper, B Mace, L Telvi, F Coutance, J W Hadden, G Renoux
  [show abstract] [hide abstract]
  ABSTRACT: In vitro long term induction of human peripheral blood lymphocytes by sodium diethyldithiocarbamate, DTC (Imuthiol) enhanced the expression of OKT and HLA-DR phenotypic determinants. A population of T-B-DR+ cells was recruited from the null cell population. The increase in OKT+ cells, but not the enhanced HLA-DR expression appeared to be macrophage dependent. The surface markers of NK cells, monocytes or the pokeweed mitogen-induced IgM production were not modified. Collectively, the findings indicate that Imuthiol is not a B cell inducer, but is specifically active on the T-cell population in the way it induces the maturation of null cells into OKT+ DR+ lymphocytes.
  International Journal of Immunopharmacology 02/1985; 7(4):561-6.
• Article: Kinetics of the histological changes in lymphoid organs and of the T-cell inducing capacity of serum in mice treated with Imuthiol (sodium diethyldithiocarbamate).

  A Pompidou, M Renoux, J M Guillaumin, B Macé, P Michel, F Coutance, G Renoux
  [show abstract] [hide abstract]
  ABSTRACT: Sodium diethyldithiocarbamate ( Imuthiol ) triggers in mice an increased production of T-cell recruiting factors and an early and prolonged hyperplasia in the T-cell dependent areas of peripheral lymphoid organs, partially independent from thymus modification. The data confirm previous findings on the role of an extrathymic factor and are consonant with the notion of a feedback regulation to control T-cell differentiation.
  International archives of allergy and applied immunology 02/1984; 74(2):172-7.
• Article: [Does immunotherapy still have a role in the treatment of cancers?].

  C Soubrane, A Pompidou, C Jacquillat
  La semaine des hôpitaux : organe fondé par l'Association d'enseignement médical des hôpitaux de Paris. 11/1983; 59(37-38):2629-31.